TERT promoter mutations are highly recurrent in SHH subgroup medulloblastoma.

Acta Neuropathol 2013 Dec 31;126(6):917-29. Epub 2013 Oct 31.

The Arthur and Sonia Labatt Brain Tumour Research Centre, The Hospital for Sick Children, Toronto, ON, Canada.

Telomerase reverse transcriptase (TERT) promoter mutations were recently shown to drive telomerase activity in various cancer types, including medulloblastoma. However, the clinical and biological implications of TERT mutations in medulloblastoma have not been described. Hence, we sought to describe these mutations and their impact in a subgroup-specific manner. We analyzed the TERT promoter by direct sequencing and genotyping in 466 medulloblastomas. The mutational distributions were determined according to subgroup affiliation, demographics, and clinical, prognostic, and molecular features. Integrated genomics approaches were used to identify specific somatic copy number alterations in TERT promoter-mutated and wild-type tumors. Overall, TERT promoter mutations were identified in 21 % of medulloblastomas. Strikingly, the highest frequencies of TERT mutations were observed in SHH (83 %; 55/66) and WNT (31 %; 4/13) medulloblastomas derived from adult patients. Group 3 and Group 4 harbored this alteration in <5 % of cases and showed no association with increased patient age. The prognostic implications of these mutations were highly subgroup-specific. TERT mutations identified a subset with good and poor prognosis in SHH and Group 4 tumors, respectively. Monosomy 6 was mostly restricted to WNT tumors without TERT mutations. Hallmark SHH focal copy number aberrations and chromosome 10q deletion were mutually exclusive with TERT mutations within SHH tumors. TERT promoter mutations are the most common recurrent somatic point mutation in medulloblastoma, and are very highly enriched in adult SHH and WNT tumors. TERT mutations define a subset of SHH medulloblastoma with distinct demographics, cytogenetics, and outcomes.

Download full-text PDF

Source
http://dx.doi.org/10.1007/s00401-013-1198-2DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC3830749PMC
December 2013
92 Reads

Publication Analysis

Top Keywords

tert promoter
16
promoter mutations
12
tert mutations
8
tert
7
mutations
6
molecular features
4
demographics clinical
4
features integrated
4
clinical prognostic
4
prognostic molecular
4
approaches identify
4
somatic copy
4
specific somatic
4
identify specific
4
genomics approaches
4
integrated genomics
4
determined subgroup
4
direct sequencing
4
sequencing genotyping
4
promoter direct
4

Altmetric Statistics

References

(Supplied by CrossRef)

RH Aaron et al.
Cancer Chemother Pharmacol 1994

H Arita et al.
Acta Neuropathol 2013

MA Blasco et al.
Nat Rev Genet 2005

P Castelo-Branco et al.
Lancet Oncol 2013

YJ Cho et al.
J Clin Oncol 2011

AM Dubuc et al.
Curr Neurol Neurosci Rep 2010

NR Forsyth et al.
Differentiation 2002

CM Heaphy et al.
Am J Pathol 2011

E Hiyama et al.
Br J Cancer 2007

S Horn et al.
Science 2013

FW Huang et al.
Science 2013

Similar Publications